OrthoPediatrics (KIDS - Free Report) reported $39.56 million in revenue for the quarter ended June 2023, representing a year-over-year increase of 20.1%. EPS of -$0.19 for the same period compares to -$0.17 a year ago.
The reported revenue represents a surprise of +1.16% over the Zacks Consensus Estimate of $39.11 million. With the consensus EPS estimate being -$0.19, the company has not delivered EPS surprise.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how OrthoPediatrics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Product sales by category- Trauma and deformity: $27.51 million compared to the $25.99 million average estimate based on three analysts. The reported number represents a change of +21.9% year over year.
- Product sales by category- Sports medicine/other: $1.15 million compared to the $1.02 million average estimate based on three analysts. The reported number represents a change of +22.7% year over year.
- Product sales by category- Scoliosis: $10.89 million versus the three-analyst average estimate of $10.72 million. The reported number represents a year-over-year change of +15.6%.
View all Key Company Metrics for OrthoPediatrics here>>>Shares of OrthoPediatrics have returned -5% over the past month versus the Zacks S&P 500 composite's +4.7% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Top 5 ChatGPT Stocks Revealed
Zacks Senior Stock Strategist, Kevin Cook names 5 hand-picked stocks with sky-high growth potential in a brilliant sector of Artificial Intelligence. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion.
Today you can invest in the wave of the future, an automation that answers follow-up questions … admits mistakes … challenges incorrect premises … rejects inappropriate requests. As one of the selected companies puts it, “Automation frees people from the mundane so they can accomplish the miraculous.”
Download Free ChatGPT Stock Report Right Now >>
OrthoPediatrics (KIDS - Free Report) reported $39.56 million in revenue for the quarter ended June 2023, representing a year-over-year increase of 20.1%. EPS of -$0.19 for the same period compares to -$0.17 a year ago.
The reported revenue represents a surprise of +1.16% over the Zacks Consensus Estimate of $39.11 million. With the consensus EPS estimate being -$0.19, the company has not delivered EPS surprise.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how OrthoPediatrics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Product sales by category- Trauma and deformity: $27.51 million compared to the $25.99 million average estimate based on three analysts. The reported number represents a change of +21.9% year over year.
- Product sales by category- Sports medicine/other: $1.15 million compared to the $1.02 million average estimate based on three analysts. The reported number represents a change of +22.7% year over year.
- Product sales by category- Scoliosis: $10.89 million versus the three-analyst average estimate of $10.72 million. The reported number represents a year-over-year change of +15.6%.
View all Key Company Metrics for OrthoPediatrics here>>>Shares of OrthoPediatrics have returned -5% over the past month versus the Zacks S&P 500 composite's +4.7% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Top 5 ChatGPT Stocks Revealed
Zacks Senior Stock Strategist, Kevin Cook names 5 hand-picked stocks with sky-high growth potential in a brilliant sector of Artificial Intelligence. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion.
Today you can invest in the wave of the future, an automation that answers follow-up questions … admits mistakes … challenges incorrect premises … rejects inappropriate requests. As one of the selected companies puts it, “Automation frees people from the mundane so they can accomplish the miraculous.”
Download Free ChatGPT Stock Report Right Now >>
Get the latest research report on KIDS - FREE